Good morning, good afternoon, and good evening, Compliance Rockstars, Clinical Research Professionals, Ethics Enthusiasts, Legal Experts, and Investigators!
โWe want to thank the leaders and members of the House and the Senate appropriations committees for the resolve and hard work so clearly demonstrated by the strong NIH provisions in this package. We are particularly grateful to Senate Labor-HHS Subcommittee Chair Shelley Moore Capito (R-WV), Ranking Member Tammy Baldwin (D-WI), House Subcommittee Chair Robert Aderholt (R-AL), and Ranking Member Rosa DeLauro (D-CT).
Even in these challenging times, the bill increases the overall NIH budget and includes new protections to help the agency fulfill its lifesaving mission. While cuts to several key research and public health agencies signal that this work is far from over, the legislation is a vast improvement over the devastating cuts included in the presidentโs FY26 budget proposal. We urge Congress to swiftly pass this legislation prior to the Jan. 30 funding deadline.โ
How did I end up reporting inaccurate information?
Remember the infamous government shutdown? Well, when Congress doesn’t approve the agency appropriation bills or a continuing resolution, the government shuts down. During a shutdown, federal agencies must discontinue all nonessential discretionary functions until new funding legislation is passed and signed into law. Only essential services and mandatory spending programs continue to function. The act that ended the government shutdown is known as a continuing resolution. A continuing resolution temporarily funds the government in the absence of full appropriations bills, often by continuing funding levels from the prior year.
So, now what?
The house and senate appropriation committees released HHS FY26 bill text (along with other agencies). Upon review of the bill text:
There was no mention of OHRP, OASH, or ASE
There wasn’t clear language regarding re-organization or consolidation of agencies within HHS
Though there will be investment into medical research, I can’t help but wonder about the compliance aspect. Rather, I’m concerned about the welfare of research participants as we enter the new year. Perhaps more details will be released (assuming Congress passes these appropriation bills). We will just have to wait and see, but you can guarantee I’ll write about it as soon as I hear anything.
Thank you for bearing with me as we navigate this complex regulatory landscape!
I always welcome folks to share information with me if what I’ve reported is incorrect or misunderstood. It is my promise and commitment to you to accurate report scientific and regulatory information.
Good morning, good afternoon, and good evening, Compliance Rockstars, Clinical Research Professionals, Ethics Enthusiasts, Legal Experts, and Investigators!
330+ subscribers and counting!
Authored By: Tasha Mohseni
Welcome to This Week Inside HHS, FDA, and the NIH!
Updates from the prior week from agencies that impact research and public health.
As a general reminder, any questions you may have about legal information within this article should be discussed with your attorney or legal counsel at your institution.
Strengthen individualsโ rights to access their own protected health information, including electronic information
Improve information sharing for care coordination and case management for individuals
Facilitate greater family and caregiver involvement in the care of individuals experiencing emergencies or health crises.
Enhance flexibilities for disclosures in emergency or threatening circumstances
Support the use of telecommunications relay services by individuals and workforce members of HIPAA covered entities and business associates who are deaf, hard of hearing, deaf-blind, or who have a speech disability
Expand the Privacy Rule permission to use and disclose protected health information of Armed Forces personnel for national readiness purposes so that it applies to all uniformed services personnel
Adam Urato, M.D., Obstetrician and Gynecologist specializing in Maternal-Fetal Medicine. Dr. Urato has held academic appointments at Harvard Medical School, the University of South Florida, and Tufts University School of Medicine. His clinical roles have included Maternal-Fetal Medicine attending positions at MetroWest Medical Center, Beth Israel Deaconess Medical Center, Boston Medical Center/St. Elizabethโs, and Tufts Medical Center. Dr. Urato received his B.A. from Harvard College and his M.D. from Harvard Medical School. He has also published extensively in peer-reviewed journals and participated in FDA advisory panels.
Kimberly Biss, M.D., Obstetrician and Gynecologist in St. Petersburg, Florida. Dr. Biss has held multiple hospital leadership positions at Bayfront Health/Orlando Health Bayfront Hospital, including Chief of Staff, Chairman of Obstetrics and Gynecology, and Medical Executive Board Officer. She is board-certified in Obstetrics and Gynecology and maintains membership in several professional medical associations. Dr. Biss received her M.D. from Tufts University School of Medicine. Her experience includes clinical education roles and publication on COVID-19 vaccine safety for pregnant women.
SAMHSA announced $231M funding opportunity to administer 988 Lifeline. The 988 Lifeline is comprised of a national network of more than 200 local crisis contact centers managed by a SAMHSA-funded 988 network administrator.
The FDA announced the availability of a draft guidance for industry entitled โUse of Bayesian Methodology in Clinical Trials of Drug and Biological Products.โ This guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials. According to this press release, this guidance is intended to satisfy the FDAโs commitment in the Prescription Drug User Fee Act (PDUFA) VII.
Nicole C. Kleinstreuer, Ph.D., has been named NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives. Prior to her current position, Dr. Kleinstreuer served as director of the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), within the National Institute of Environmental Health Sciences (NIEHS). She is deeply committed to mentorship, public health protection, and scientific innovation.
NIH shared a video update on what reviewers are saying about the Simplified Review Framework (SRF). SRF has been used for peer review on the majority of competing research project grant (RPG) applications in summer 2025.
Good morning, good afternoon, and good evening, Compliance Rockstars, Clinical Research Professionals, Ethics Enthusiasts, Legal Experts, and Investigators!
It can be easy to miss the bigger picture. This inspired me for today’s topic.
Advertisements
Let’s dive right in!
I’m going to cover the re-organization of the Department of Health and Human Services (HHS) and how how this impacts the Office of Human Research Protections (OHRP). Specifically, I’d like to highlight:
The current HHS structure with OHRP under the Office of the Assistant Secretary for Health (OASH)
Introduce the Assistant Secretary of Enforcement (ASE)
Close with how I envision OHRP under the new ASE
As a general reminder, any legal information discussed within this post should be discussed with your institution.
Table of Contents:
What is OASH?
The Office of the Assistant Secretary of Health (OASH) develops policy recommendations for public health across HHS and its agencies. OASH is tasked with improving the health and well-being of Americans by leading on policy, practices, and programs. OASH seeks to restore scientific integrity and transparency to rebuild public trust and advance the public good. Below is the current organizational structure:
OHRP is one of these divisions that supports OASH.
OHRP fulfills responsibilities set forth in the Public Health Service (PHS) Act including:
Providing leadership for human research subjects protections within HHS and for the U.S. Government in cooperation with other Federal Agencies
Developing and monitoring as well as exercising compliance oversight relative to HHS regulations for the protection of human subjects in research conducted or supported by any component of HHS
Promoting and coordinating appropriate HHS regulations, policies, and procedures both within HHS and in coordination with other Departments and Agencies in the Federal Government
Establishing criteria for approval of assurances of compliance for the protection of human subjects with both domestic and foreign institutions engaged in HHS-conducted or supported research involving human subjects
Conducting programs of clarification and guidance for both the Federal and non-Federal sectors with respect to the involvement of humans in research; and directing the development and implementation of educational and instructional programs and generating educational resource materials
Evaluating the effectiveness of HHS policies and programs for the protection of human subjects
Serving as the liaison to Presidential, Departmental, Congressional, interagency, non-governmental, and international commissions and boards to examine ethical issues in medicine and research and exercises leadership in identifying and addressing such ethical issues
Promoting the development of approaches to enhance and improve methods, particularly quality improvement at the institutional level, to avoid unwarranted risks to humans participating as subjects in research covered by applicable statutes
Within this initiative, the Assistant Secretary for Enforcement (ASE) is introduced: “HHS will create a new Assistant Secretary for Enforcement to oversee the Departmental Appeals Board (DAB), Office of Medicare Hearings and Appeals (OMHA), and Office for Civil Rights (OCR) to combat waste, fraud, and abuse in federal health programs.”
Now that we have some background information, let’s talk about ASE.
Directly from the HHS FY26 budget justification, ASE will centralize executive oversight over several mission-critical offices:
Departmental Appeals Board (DAB)
Office for Civil Rights (OCR)
Office of Medicare Hearings and Appeals (OMHA)
Office for Human Research Protections (OHRP)
This consolidation is designed to streamline oversight, improve enforcement and adjudication coordination, provide education and guidance on relevant legal authorities, and strengthen HHS’s ability to fulfill its legal obligations to the public. ASE will:
Ensure individuals and institutions attain resolution of complaints, disputes, and appeals
Encourage compliance through regulations, guidance, education, and technical assistance
Enforce legal compliance and adjudication under federal statutes and regulations
As someone with an accounting and program management background, I can appreciate cutting costs. Having said that…
Cost reduction should NOT equal mission reduction.
OHRP’s mission will take an even bigger blow.
I was alarmed when I didn’t see OHRP mentioned in the HHS press release or fact sheet.
In the press release, it was indicated that ASE would be comprised of DAB, OMHA, and OCR. Further, it was noted in the fact sheet that “A new Administration for a Healthy America (AHA) will consolidate the OASH, HRSA, SAMHSA, ATSDR, and NIOSH, so as to more efficiently coordinate chronic care and disease prevention programs and harmonize health resources to low-income Americans.” This made me wonder…where is OHRP in the midst of this?
Reviewing OHRP’s approved budget is an even sadder story.
I did feel some relief once I saw OHRP was mentioned within the HHS FY26 budget justification. However, it slowly disappeared as I read through the budget requests for each unit. HHS signaled where OHRP falls on the totem pole. Directly copied from the budget justification:
“The Office for Human Research Protection also requests non-trust fund budget authority that will maintain minimal operations. This includes conducting a limited number of for-cause compliance assessments of human research protection programs or institutional review boards, processing approximately 800-1,000 incident reports, and approximately 400-600 complaints about research. Develop guidance, the fulfillment of the FWA and IRB registration missions, and the ability to develop educational tools and resources will be limited.”
OHRP already had limited staff and resources with great responsibility. How is OHRP supposed to act on their duties under the PHS Act when the budget request is so specific? I have so many questions about this budget request:
What is considered a “limited number” of for-cause compliance assessments?
How is OHRP supposed to prioritize which HRPPs and IRBs receive such assessments?
What happens if there’s more complaints and/or incidents than originally projected?
Why are resources (i.e., educational tools) and enforcement mechanisms (i.e., FWA) that uphold public trust in research on the back burner?
OHRP is going to need support and expertise from research compliance professionals such as ourselves for education and guidance development. NACHRP and PRIM&R could potential lead such efforts.
Good morning, good afternoon, and good evening, Compliance Rockstars, Clinical Research Professionals, Ethics Enthusiasts, Legal Experts, and Investigators!
330+ subscribers and counting!
Authored By: Tasha Mohseni
Wow, what a busy start to the new year!
I always think each new year should begin with pause and planning. Planning for personal and professional goals. Planning for family trips. Just planning in general. However, it already feels like I’m in the 2026 hamster wheel. You would think I’d be used to this by now, but I suppose not.
Advertisements
Let’s dive into today’s topic!
I’m going to cover select recent developments within HHS and its agencies including:
Food and Drug Administration (FDA)
National Institutes of Health (NIH)
Office of Research Integrity (ORI)
As a general reminder, any legal information discussed within this post should be discussed with your institution.
Public comment requested on the adoption and use of AI in clinical care
The Department of Health and Human Services (HHS) issued a Request for Information (RFI) on accelerating the adoption and use of AI in clinical care. Public feedback will inform HHS-wide use of three different approaches: regulation, reimbursement, and research & development. Specifically, HHS seeks concrete, experience-based feedback from those building, buying, evaluating, using, and receiving care from AI tools that are part of clinical care as well as from those who wish to do so but face barriers. The RFI has a 60-day comment period from when the notice was first issued.
HHS, via the ASTP/ONC, released the HTI-5 Proposed Rule. A central component of the HTI-5 Proposed Rule is streamlining the ONC Health IT Certification Program. The HTI-5 Proposed Rule also includes updates to the information blocking regulations. Drawing from stakeholder feedback, the proposal edits definitions and adjusts several exceptions to reduce the potential for misuse and to strengthen HHSโs ability to ensure patient access to electronic health information. The Proposed Rule will be open for public comment for 60 days upon publication in the Federal Register.
(Back to the Contents)
HHS grand AI strategy
HHS released a comprehensive AI strategy designed to transform how the agency operates, serves the public, and accelerates innovation across health, human services, and public health. This marks a significant milestone in HHSโs efforts to harness AI responsibly and effectively to improve outcomes for all Americans. This framework that expands the responsible use of AI throughout the Department and aligns with broader federal directives to modernize government operations and innovation. Further, the strategy centers on a OneHHS approach uniting AI priorities and governance across all HHS agencies. The plan is built upon five main pillars:
Ensure governance and risk management for public trust
Design infrastructure and platforms for user needs
Promote workforce development and burden reduction for efficiency
Foster health research and reproducibility through gold standard science
Enable care and public health delivery modernization for better outcomes
As part of this initiative, HHS published its AI Compliance Plan in late 2025. This plan implements the requirements of the Office of Management and Budgetโs (OMB) Memoranda M-25-21 and M-25-22, which directs federal agencies to accelerate the safe, innovative, and trustworthy use of AI. The Compliance Plan focuses on three areas:
Encouraging public trust by promoting transparency and accountability in AI use
Driving innovation via removal of barriers and enabling efficient adoption of AI
Placing AI governance at the forefront by establishing policies, inventories, and oversight processes across HHS Divisions
Top FDA drug regulator Pazdur retires, Hรธeg takes his place in CDER
The FDA continues to switch up the game with grand regulatory changes. STAT first reported Richard Pazdurโs retirement from the FDAโs Center for Drug Evaluation and Research (CDER) just weeks after acceptance. FDA Commissioner Dr. Marty Makary first appointed Pazdur mid-November calling him a true regulatory innovator. Though his departure appeared abrupt, itโs not necessarily a shock. CNN reported that Pazdur initially turned down the CDER appointment primarily because of his strained relationship with Dr. Vinay Prasad.
Years prior, Prasad openly criticized Pazdur in a blog post stating, โFrankly Rick Pazdur has exerted his will over the FDA and has done a catastrophically bad job.โ
GAO calls for action in medical device recall oversight limitations
The Government Accountability Office (GAO) recently published a report on the FDAโs medical device recall process. The FDA monitors the safety of approximately 200,000 medical devices. From 2020 to 2024, the GAO reported that nearly 4,000 of these devices needed to be recalled. Using recalled medical devices can lead to serious injury, death, or other adverse effects.
FDA’s oversight of the recall process includes reviewing manufacturers’ recall plans and verifying that recalls were carried out according to plan.
Gaps in this oversight process not only magnify inefficiencies, but also places patients at risk. The ramifications of using recalled devices include the potential for serious injury or death. FDAโs oversight of medical products, including devices, has been on GAOโs high-risk list since 2009.
In February 2026, the FDA will begin enforcing the Quality Management System Regulation (QMSR). This replaces the Quality System Regulation (QSR) under 21 CFR 820 and is aligned with the international standard specific for medical device quality management systems set by the International Organization for Standardization (ISO) ISO 13485:2016. The December 2025 technical amendments are purely administrative revisions made by the FDA to align 21 CFR 820 with the QMSR framework.
The QMSR harmonizes key areas of a device manufacturerโs Quality Management System (QMS) and more closely aligns the U.S. with many other regulatory authorities around the world.
Further, this action promotes consistency in the regulation of devices and provides a timelier introduction of safe, effective, high-quality devices for patients.
Organizations can start communications early with key stakeholders to facilitate the understanding of shifting from QSR to QMSR. If your organization currently implements ISO 13485, they should review for any potential compliance gaps from the FDA QMSR (e.g., additional requirements or documentation). After gap analysis is performed, organizations can create training materials to educate staff. Further, any templates used to review for medical device studies should be updated for terminology changes from QSR to QMSR.
RFI on harmonizing NIH research participant data policies
The NIH issued a RFI inviting public input on a significant proposal to harmonize and improve how human research participant data are protected and shared across NIH policies. This initiative reflects NIHโs commitment to responsible data stewardship. Under NOT-OD-26-023, NIH proposes to:
A new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations
This policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types
To revise the NIH Genomic Data Sharing (GDS) Policy to reduce duplicate policy requirements and improve overall performance with respect to human genomic data only
NIH welcomes comments with respect to:
Whether the proposed data types requiring controlled access are appropriate
Suggested additions or modifications to definitions or criteria
Practical considerations for implementation
Views on the proposed scope of the revised GDS Policy
Recent statement from NIH Director Bhattacharya on engaging the public as clinical research partners
The NIH director issued a statement titled โRoadmap for Engaging the Public as Partners in Clinical Research,โ which signals a new era of participation, transparency, and shared ownership in the research. The roadmap reflects recommendations from the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) and its ENGAGE Working Group, which spent several years consulting experts and communities nationwide to identify ways to integrate public voices at every stage of clinical research. This includes:
Helping interpret and disseminate results in ways that matter to peopleโs lives
Designing research questions that align with community priorities
Advising on recruitment strategies and study plans
A cornerstone of this initiative is transparency about how clinical research data are used and shared. To support transparency, NIH is establishing agency-wide principles to foster, promote, and guide the responsible conduct of research using clinical data. The eight priniciples are as follows:
Leveraging existing infrastructure to promote access and improve efficiencies in cost and resources is a NIH-wide priority
Demonstrating respect for persons is a core NIH value when considering research uses of clinical data
Ensuring responsible stewardship of data is an essential component of demonstrating respect for persons
Recognizing the needs of the communities from which the data are collected and generated is imperative to respectful collaboration or partnerships on using clinical data for research
Fostering and maintaining public trust necessitates ongoing transparency regarding uses of clinical data for research and communication of the potential benefits and risks of such research
Promoting quality of EHR data that is beneficial for both clinical and research use should be accompanied by a recognition that data in the EHR was collected specifically for clinical use
Deciding to use clinical data for research purposes requires ongoing consideration of the risks and benefits, NIHโs unifying principles, and the core principles captured in current laws, policies, and regulations
Ensuring that policies and decision-making processes regarding the use of clinical data for research purposes are designed to adapt to rapidly changing technical, social, ethical, and regulatory landscapes is essential
The NIH implemented research security training requirements as outlined in the CHIPS and Science Act of 2022. Several federal agencies including the NSF and DOE are implementing training requirements that address cybersecurity, international collaboration, foreign interference, and rules for proper use of funds, disclosure, conflict of commitment, and conflict of interest. This initiative safeguards U.S. scientific research.
The NSF, in partnership with the NIH, the DOE, and DOD, have created four online research security training (RST) modules as a resource for organizations to fulfill this requirement. The condensed RST module is designed to meet the government-wide RST requirement in the CHIPS and Science Act of 2022. To that end, NSF, NIH, DOE, DOD, and USDA all recognize completion of the condensed module as compliant with their respective RST requirements.
Completion of this training as well as individual and institutional certifications will be effective for applications submitted for due dates on or after May 25, 2026. Organizations can ensure this requirement is communicated to investigators engaged in NIH-funded research. They can ensure covered individuals (those defined as senior/key personnel) listed on the grant certify completion of this training within 12 months of the date of application submission. Note that covered individuals may be defined differently depending on the specific federal agency.
The Office of Research Integrity (ORI) released a new set of guidance documents to support institutions preparing for the implementation of the 2024 Final Rule on Public Health Service (PHS) Policies on Research Misconduct. These resources are designed to help institutions better understand and comply with the updated regulations, which became effective January 1, 2026. New topic-specific guidance documents released include:
Institutional Records (pdf): This document is designed to assist institutions in producing a complete institutional record including reports, interviews, research records, and other documents and information compiled during a research misconduct proceeding.
Research Records (pdf): This document describes the wide range of research records and other evidence that may be needed to complete a research misconduct proceeding.
Multiple Institutions (pdf): This guidance document is intended to help institutions navigate research misconduct proceedings involving multiple institutions.
Good morning, good afternoon, and good evening, Compliance Rockstars, Clinical Research Professionals, Ethics Enthusiasts, Legal Experts, and Investigators!
330+ subscribers and counting!
Authored By: Tasha Mohseni
Happy New Year and welcome to the first CREST blog post in 2026!
It feels good to get back on the saddle and write to you all. I hope you all enjoyed the holidays with your family and loved ones.
I wish that 2026 brings you all success, good health, and whatever you were working towards last year that will be worthwhile.
For today’s article, I’d like to highlight top research administration and compliance conferences. These are events you don’t want to miss to develop professionally!
IMPORTANT: Events within this article were included only if they were a “conference” or “annual meeting” (i.e., no other event types such as workshops or webinars).
Advertisements
As a general reminder, these are my own interpretations. Any legal information discussed within this post should be discussed with your institution.
MAGI is a WCG event that connects clinical research professionals who are committed to ensuring the quality, compliance, and efficiency.
Per the website, WCG is a partner to research sponsors, CROs, sites and participants in navigating the clinical research journey. WCG showcases their solutions in exhibit booths at various conferences. Further, they offer informative webinars (especially if you’re new to clinical research. You can view the following links below for educational materials:
Budgets: learning the nuances of ensuring your site is optimized for conducting clinical trials
Contracts: exploring field-tested, easily implemented negotiation tools and techniques that can help maintain control, improve turnaround times, and reduce last-minute scrambles
Billing compliance: strengthening research billing compliance development and program oversight
Quality and regulatory: ensuring adherence to the regulations on research participant protections
Clinical operations: mastering approaches to maintaining trial quality and effective tactics for protecting participant safety and data integrity
You can review the 2025 agenda to view workshops within these educational tracks
The PRIM&R Conference educates those involved in research and research oversight to support and achieve the advancement of ethical, responsible, and high-quality research.
PRIM&R is a nonprofit,โฏfounded in 1974 that works to ensure the highest ethical standards in research by:
Providing education,
Membership, and
Other professional resources to the research and research oversight community, including those who work with:
Human research protections programs (HRPPs),
Institutional review boards (IRBs),
Animal care and use programs,โฏand
Institutional animal care and use committeesโฏ(IACUCs).
Those who attend these conferences can use the session materials in preparation for the following certifications:
This also includes the PRIM&R Social Behavioral Educational Research Conference (SBER25). Attendees have the choice to either:
Attend PRIM&R 2025 only
Attend SBER 2025 only
Attend PRIM&R 2025 and SBER25
Educational tracks range from program administration, regulation-specific topics, quality control, post approval monitoring, emerging challenges, and many more!
NWABR offers three annual conferences and is currently accepting 2026 submissions.
NWABR is dedicated to promoting the public’s trust in ethically conducted biomedical research. You can read more about this organization here: About Us.
IRB, IBC & IACUC Conference Series
This conference is PERFECT if you wear multiple compliance hats or in a small HRPP.
You can review the 2025 program to see the various topics within these compliance areas.
Clinical Research Professional Conference Series
This conference is for clinical research professionals who ensure the ongoing integrity of research within their institutions.
You can review the 2025 program to see this year’s focus: quality initiatives and artificial intelligence (AI)
CyberBIO Conference Series
This conference includes experts across government, industry, and academia to discuss issues at the intersection of biomedical sciences and cybersecurity.
You can review the 2025 program once it is available (as of 9/23/25).
Clinical Research Project/Program Management Conference
This conference is designed to introduce, affirm, or elevate your understanding of project management in the field of clinical research.
The program will broaden the participantsโ knowledge of the regulatory framework, project management, planning and accounting, and achieving successful clinical trials. For more details, you can review:
This conference provides insights, practical tools, and real-life examples to navigate quality planning, control, assurance, and improvement in clinical research.
The event delivers vital information on developing and implementing effective quality management systems in line with FDA Regulations and ICH guidance. For more details, you can review:
FDA Clinical Trial Requirements, Regulations, Compliance and GCP Conference
This conference is designed to aid in the understanding of the FDA’s mission, responsibilities and authority and to facilitate interaction with FDA representatives.
The conference will focus on:
FDA Clinical Research Requirements,
Enhancing Success through Communication, and
Financial Incentives, and Assuring Confidence in Clinical Research
This conference will improve professional skills and understanding of the responsibilities of conducting clinical research in the pediatric population.
This program is designed to elevate attendees’ understanding and application across the:
SRAI provides research administrators globally with the knowledge, resources, and community they need to excel, collaborate, and drive impactful research.
Directly from the website, this organization is the only research management society in the world whose membership spans the entire spectrum of research institutions, including:
For-profit entities involved in research and development
Public and private colleges and universities
Research hospitals and institutes
Charitable and research-focused nonprofits
Federal, state, and local government bodies engaged in research
Annual Meeting
Folks who attend the SRAI 2026 conference will gain fresh perspectives on timely topics from the world’s leading research administration experts.
Sponsored Programs Planning, Development and Deliveries
Technology Solutions in Research Administration
Financial Management Conference
The Financial Management Conference is a virtual professional development event focused on financial and post-award management in research administration.
Sponsored Programs Planning, Development and Deliveries